Research opportunities in clinical research

We support a broad portfolio of clinical and translational research through response mode funding, initiatives and investments in clinical infrastructure.

We aim to maximise patient impact through high-impact early phase and first-in-man trials, ambitious and innovative trial designs, and our core-funded supporting infrastructure, which together enable us to learn as much as we can from the patients on our trials. We are also committed to ensuring that clinical academics have the support they need to develop a career in cancer research, and we have a range of opportunities for clinical researchers at all career levels.

Strategic priorities

Strategy statement - we will learn as much as we can from the  patients on our trials

Our overarching aims are to maintain a broad portfolio of clinical research that maximises patient impact, and to learn as much as we can from the patients on our trials.

We have set out our priorities, and how we intend to achieve them, in our clinical research statement of intent, which is used as a basis for strategic discussion by the Clinical Research Committee.

Infrastructure

Funding by location map

Our core-funded infrastructure provides specialist expertise and operational support which you may be able to access as part of your clinical research.

Clinical Trials Units (CTUs)

Our eight CTUs help investigators design, conduct, analyse and publish clinical trials of all phases.

Experimental Cancer Medicine Centre (ECMC) Network

The ECMC Network of 18 virtual Centres supports early-phase clinical trials and translational research.

Our research collaborations

Making progress as quickly as possible means working in partnership with others, especially in areas of research that are hard to deliver.

Stratified Medicine Programme
Our pioneering initiative is bringing the benefits of genetic testing to cancer patients and researchers across the UK.

The International Rare Cancers Initiative (IRCI)
We are a founder member of IRCI, which facilitates the development of international clinical trials for patients with rare cancers.

Rate this page:

Currently rated: 2.5 out of 5 based on 2 votes

Share this page